Patent expiry and biosimilars: difference between revisions
Diff·revision 29 → 30·15:28, 14 Jul 2026
Difference between revision 29 and revision 30 of Patent expiry and biosimilars. This revision changed no lines of source — the edit was a null or whitespace change.
| Revision 29 — 16:46, 16 Jun 2026 ShortageShona (talk) state that research-use-only labelling is a commercial category, not an approval 4,553 bytes ±0 | Revision 30 — 15:28, 14 Jul 2026 PeakShapePol (talk) add the jurisdiction to the legal statement 4,553 bytes ±0 | ||
|---|---|---|---|
| — | No change to the page source. | — |